Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.

Autor: Ikezawa Y; Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan.; Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan., Morita R; Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan., Mizugaki H; Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.; Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Tateishi K; First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan., Yokoo K; Department of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Japan., Sumi T; Department of Respiratory Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan., Kikuchi H; Department of Respiratory Medicine, Obihiro-Kousei General Hospital, Obihiro, Japan., Kitamura Y; Department of Respiratory Medicine, Kushiro City General Hospital, Kushiro, Japan., Nakamura A; Department of Pulmonary Medicine, Sendai Kousei General Hospital, Sendai, Japan., Kobayashi M; Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan., Aso M; Department of Respiratory Medicine, Yamagata Prefectural Central Hospital, Yamagata, Japan., Kimura N; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan., Yoshiike F; Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan., Megumi F; Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan., Tanaka H; Department of Respiratory Medicine, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan., Sekikawa M; Department of Respiratory Medicine, Steel Memorial Muroran Hospital, Muroran, Japan., Hachiya T; Department of Respiratory Medicine, Japanese Red Cross Suwa Hospital, Suwa, Japan., Nakamura K; Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan., Hommura F; Department of Respiratory Medicine, Sapporo City General Hospital, Sapporo, Japan., Sukoh N; Department of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan., Ito K; Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan., Kikuchi T; Department of Respiratory Medicine, Iwate Prefecture Isawa Hospital, Oshu, Japan., Agatsuma T; Department of Respiratory Medicine, Shinshu Ueda Medical Center, Ueda, Japan., Yokouchi H; Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2024 Jul; Vol. 13 (14), pp. e70036.
DOI: 10.1002/cam4.70036
Abstrakt: Background: Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression is an important issue in clinical practice. We previously conducted a retrospective multicenter observational study of patients with NSCLC and high PD-L1 expression who received MONO or COMB as a first-line treatment. Here, we report updated data and evaluate the long-term outcomes.
Methods: We performed a retrospective multicenter study of 298 patients with NSCLC and high PD-L1 expression who received MONO or COMB as first-line treatment between December 2018 and January 2020. We reviewed the medical records and assessed the clinical efficacy and toxicity using a prolonged data cutoff.
Results: In total, 164 (median age: 74 years) and 134 (median age: 68 years) patients received MONO and COMB, respectively; patients who received COMB were younger and had better performance statuses (0-1). At the prolonged data cutoff, the median follow-up was 20.2 (range: 0.1-41.4) months. The median progression-free survivals were 7.5 and 13.1 months, and overall survivals (OSs) were 17.2 and 33.7 months for MONO and COMB, respectively. Treatment discontinuation rates were 21.9% and 20.1% for the MONO and COMB, respectively. With prolonged follow-up, although COMB demonstrated an OS benefit and higher objective response rate than MONO, in the propensity score matching analysis COMB didn't demonstrate a significant benefit compared to the MONO.
Conclusions: COMB may be effective as a first-line treatment for NSCLC with high PD-L1 expression in a selected subset of patients.
(© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje